Changes in 2'-deoxycytidine levels in various tissues of tumor-bearing mice

Oncology Letters

Volumn 1, Issue 6, 2010, Pages 999-1004

  Iwazaki, Ayano ^a   Imai, Kimie ^a   Nakanishi, Kunio ^a   Yoshioka, Masanori ^a  

^a SETSUNAN UNIVERSITY   (Japan)

Author keywords

5 fluorouracil; Spleen; Tumor volume

Indexed keywords

BIOLOGICAL MARKER; DEOXYCYTIDINE; FLUOROURACIL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; CANCER INHIBITION; CELL STRAIN; CELL STRAIN SP2 0 AG 14; CONTROLLED STUDY; DRUG MECHANISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER LEVEL; LIVER WEIGHT; MALE; MOUSE; MYELOMA CELL; NONHUMAN; PROTEIN BLOOD LEVEL; SOLID TUMOR; SPLEEN WEIGHT; TISSUE LEVEL; TUMOR VOLUME;

EID: 77957939338     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2010.170     Document Type: Article

References (19)

1. Ahmed WA, Ali-Din NH, Yoshioka M and EL-Merzabani M: 2'-Deoxycytidine (DCYD) as a potential biological marker for detecting acute lymphocytic leukemia and bladder cancer. J Union Arab Biol Cairo 20A: 97-111, 2003.
2. Ahmed WA, Moneer M, Abo-Shady MM, Mansour HH, Abd-El-Wahab N, Yoshioka M and EL-Merzabani M: 2'-Deoxycytidine as a potential biomarker for detection of hepatocellular carcinoma. Egyptian J Hosp Med 21: 191-201, 2005.
3. Yoshioka M, Abu-Zeid M, Kubo T and El-Merzabani M: Identification of a previously unknown compound as 2'-deoxycytidine found in the plasma of breast cancer patients under combined chemotherapy. Biol Pharm Bull 17: 169-174, 1994.
4. Iwazaki A and Yoshioka M: 2'-Deoxycytidine decreases the anti-tumor effects of 5-fluorouracil on mouse myeloma cells. Biol Pharm Bull 33: 1024-1027, 2010.
5. Moyer JD, Malinowski N and Ayers O: Salvage of circulating pyrimidine nucleosides by tissues of the mouse. J Biol Chem 260: 2812-2818, 1985.
6. Rossi L, Serafini S, Schiavano GF, Casabianca A, Vallanti G, Chiarantini L and Magnani M: Metabolism, mitochondrial uptake and toxicity of 2', 3'-dideoxycytidine. Biochem J 344: 915-920, 1999.
7. Berlinger WG, Stene RA, Spector R and Al-Jurf AS: Plasma and cerebrospinal fluid nucleosides and oxypurines in acute liver failure. J Lab Clin Med 110: 137-144, 1987.
8. Schneider WC and Behki RM: Phosphorus compounds in animal tissues. VII. Enzymatic formation of deoxycytidine diphosphate choline and lecithin by tissue homogenates. J Biol Chem 238: 3565-3571, 1963.
9. Osogoe B and Ueki A: A radioautographic study of the utilization of deoxycytidine for the formation of deoxyribonucleic acid-thymine in lymphocytes. J Cell Biol 46: 403-405, 1970.
10. Osogoe B, Tyler RW and Everett NB: The patterns of labeling of germinal-center cells with tritiated deoxycytidine. J Cell Biol 57: 215-220, 1973.
11. Muramatsu M, Kinoshita K, Fagarasan S, Yamada S, Shinkai Y and Honjo T: Class switch recombination and hypermutation require activation-induced cytidine deaminase (AID), a potential RNA editing enzyme. Cell 102: 553-563, 2000.
12. Muramatsu M, Sankaranand VS, Anant S, Sugai M, KinoshitaK, Davidson NO and Honjo T: Specific expression of activation-induced cytidine deaminase (AID), a novel member of the RNA-editing deaminase family in germinal center B cells. J Biol Cell 274: 18470-18476, 1999.
13. Kotani A, Okazaki I, Muramatsu M, Kinoshita K, Begum NA, Nakajima T, Saito H and Honjo T: A target selection of somatic hypermutations is regulated similarly between T and B cells upon activation-induced cytidine deaminase expression. Proc Natl Acad Sci USA 102: 4506-4511, 2005.
14. Harris RS, Petersen-Mahrt SK and Neuberger MS: RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Mol Cell 10: 1247-1253, 2002.
15. Okazaki IM, Hiai H, Kakazu N, Yamada S, Muramatsu M, Kinoshita K and Honjo T: Constitutive expression of AID leads to tumorigenesis. J Exp Med 197: 1173-1118, 2003.
16. Chan TS, Lakhchaura BD and Hsu TF: Differences in deoxycytidine metabolism in mouse and rat. Biochem J 210: 367-371, 1983.
17. Miwa M, Eda H, Ura M, Ouchi KF, Keith DD, Foley LH and Ishitsuka H: High susceptibility of human cancer xenografts with higher levels of cytidine deaminase to a 2'-deoxycytidine antimetabolite, 2'-deoxy-2'-methylidenecytidine. Clin Cancer Res 4: 493-497, 1998.
18. Chen EH, Johnson EE II, Vetter SM and Mitchell BS: Characterization of the deoxycytidine kinase promoter in human lymphoblast cell lines. J Clin Invest 95: 1660-1668, 1995.
19. Hapke DM, Stegmann AP and Mitchell BS: Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Cancer Res 56: 2343-2347, 1996.